Left Atrial Inflow Ventricular Assist Device Utilization in Patients With Small or Restrictive Left Ventricles: A Systematic Review
- 30 July 2026
- journal article
- review article
- Published by Wiley in Artificial Organs
- Vol. 50 (9) , 1207-1216
Abstract
Background: Conventional mechanical circulatory support offers limited options for patients with small or restrictive left ventricles. Left atrial inflow (LA–Ao) ventricular assist device (VAD) configuration represents an alternative to conventional apical left ventricular assist device (LVAD). However, outcomes data remain limited. To address this, we evaluated patient characteristics, procedural details, and outcomes of LA–Ao VAD configuration in this population. Methods: A systematic search was conducted to identify case reports and series of patients with small or restrictive left ventricles who underwent LA–Ao LVAD implantation. A total of 21 reports, representing 27 patients, were included. Patient‐level data were extracted for analysis. Results: Thirteen adult and 14 pediatric patients underwent LA–Ao VAD implantation. Median age was 57 [46–62] years in adults and 3.5 [0.8–9] years in children. Hypertrophic cardiomyopathy and restrictive cardiomyopathy were the predominant diagnoses in both adults and children, accounting for 54% (7/13) and 29% (4/14), and 46% (6/13) and 43% (6/14), respectively. Median left ventricular ejection fraction was 44% [39–53] in adults and 45% [36–61] in children, and median left ventricular end‐diastolic diameter was 42 [35–42] mm in adults and 33 [29–34] mm in children. The most used devices were HeartWare HVAD (46%, 6/13) in adults, and Berlin Heart (64%, 9/14) in children. Overall pulmonary capillary wedge pressure decreased from 23 [19–27] to 7 [0–9] mmHg ( p = 0.02), and cardiac index increased from 2.0 [1.3–2.8] to 3.1 [2.7–3.7] L/min/m 2 ( p = 0.04). In‐hospital mortality included one fatal case (7.7%) in each group. Overall survival was 85% (11/13) in adults at median follow‐up of 6.7 [4.4–19.9] months and 86% (12/14) in children at 2.3 [1.2–8.1] months. Conclusion: The LA–Ao configuration of VAD is a viable strategy for mechanical circulatory support in patients with small or restrictive left ventricles. It offers effective unloading of the left atrium and improved cardiac index, supporting its role as an alternative to the conventional LVAD approach.Keywords
This publication has 20 references indexed in Scilit:
- Trans-atrial Inflow Cannula Configuration for Durable HeartWare Left Ventricular Assist Device in Hypertrophic Cardiomyopathy: A Case Series and a Word of CautionJHLT Open, 2025
- A less-invasive left atrial assist device concept for diastolic heart failure: First in vitro and in vivo assessmentJTCVS Open, 2024
- Advanced Heart Failure Therapies for Hypertrophic CardiomyopathyJACC: Heart Failure, 2023
- Left Ventricular Assist Device and the Current State of the Art: HeartMate 3 at 5 YearsHeart Failure Clinics, 2023
- Left Ventricular Assist Device With a Left Atrial Inflow Cannula for Hypertrophic CardiomyopathyJACC: Case Reports, 2020
- Presence of Left Atrial or Left Ventricular Thrombus at the Time of CF-LVAD Implantation is Associated with Increased Post-Operative Risk of Stroke or DeathThe Journal of Heart and Lung Transplantation, 2019
- Primary and Secondary Diastolic Dysfunction in Heart Failure With Preserved Ejection FractionThe American Journal of Cardiology, 2018
- An Alternative Approach by HeartWare Ventricular Assist Device in Hypertrophic CardiomyopathyThe Annals of Thoracic Surgery, 2018
- Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS AnalysisJournal of Cardiac Failure, 2017
- Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal diseaseThe Journal of Heart and Lung Transplantation, 2015